Bimekizumab Pain Outcomes in Patients with Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II Phase 3 Randomized Clinical Trials.

Ingram JR, Fujita H, Gottlieb AB, Lev-Tov H, Prens E, Sayed CJ, Shi VY, Szepietowski JC, Takahashi K, Frew JW, Lambert J, Davis L, Oh T, Rolleri R, Saintmard MH, Orenstein LAV

Open source

DOI: 10.1007/s40122-025-00779-7
Published: 2025 Dec
Container: Pain and therapy
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s40122-025-00779-7,
  title = {Bimekizumab Pain Outcomes in Patients with Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I\&II Phase 3 Randomized Clinical Trials.},
  author = {Ingram JR and Fujita H and Gottlieb AB and Lev-Tov H and Prens E and Sayed CJ and Shi VY and Szepietowski JC and Takahashi K and Frew JW and Lambert J and Davis L and Oh T and Rolleri R and Saintmard MH and Orenstein LAV},
  year = {2025},
  journal = {Pain and therapy},
  doi = {10.1007/s40122-025-00779-7},
  url = {https://doi.org/10.1007/s40122-025-00779-7}
}

RIS

TY  - JOUR
TI  - Bimekizumab Pain Outcomes in Patients with Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II Phase 3 Randomized Clinical Trials.
AU  - Ingram JR
AU  - Fujita H
AU  - Gottlieb AB
AU  - Lev-Tov H
AU  - Prens E
AU  - Sayed CJ
AU  - Shi VY
AU  - Szepietowski JC
AU  - Takahashi K
AU  - Frew JW
AU  - Lambert J
AU  - Davis L
AU  - Oh T
AU  - Rolleri R
AU  - Saintmard MH
AU  - Orenstein LAV
PY  - 2025
JO  - Pain and therapy
DO  - 10.1007/s40122-025-00779-7
UR  - https://doi.org/10.1007/s40122-025-00779-7
ER  -

APA

JR, I., H, F., AB, G., H, L., E, P., CJ, S., VY, S., JC, S., K, T., JW, F., J, L., L, D., T, O., R, R., MH, S., & LAV, O. (2025). Bimekizumab Pain Outcomes in Patients with Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II Phase 3 Randomized Clinical Trials.. Pain and therapy. https://doi.org/10.1007/s40122-025-00779-7

Source records

pubmed · retrieved 2026-09-26T14:28:48.371Z